Phage P1 loxP sites, mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, rtTA[E. coli tet repressor (TetR), herpes simplex virus (HSV) VP16 activation domain], mouse developmental pluripotency-associated 3 (PGC7) genomic DNA
    
    C (3-6 months)
    
    
    
    Cre/loxP system
    中村 肇伸
    Dppa3 (PGC7/Stella) 遺伝子のノックアウトマウス (rtTAノックインマウス) 。Dppa3遺伝子の開始コドンをrtTA cDNAとfloxed PGK-neoで置換。雄のホモは繁殖に異常はないが、雌のホモは不妊となる。
    
    
    Dppa3 (PGC7/Stella) gene knockout (rtTA knock-in mice).  The start codon of Dppa3 was replaced with rtTA cDNA and floxed PGK-neo cassette.  Dppa3 gene plays a critical role in embryonic development as a maternal facotor.  Homozygote males mice are fully fertile, but homozygous females are infertile.
    Developed by Toshinobu Nakamura, Toru Kimura and Toru Nakano, Graduate School of Medicine and Frontier Biosciences, Osaka University in 2003.  D3 ES cells were used to generate the mutant mice.  The mice were crossed to C57BL/6 (C57BL/6 semicongenic).
    
    
    
    
    
    国立大学法人大阪大学
    
    
    C(3〜6か月)
    D3 [129S2/SvPas]
    Dppa3 (PGC7/Stella) 遺伝子のノックアウトマウス (rtTAノックインマウス) 。Dppa3遺伝子の開始コドンをrtTA cDNAとfloxed PGK-neoで置換。雄のホモは繁殖に異常はないが、雌のホモは不妊となる。,
    
    
    
    Tet system
    
    
    RBRC01494
    
    
    PGC7 KO
    PGC7 KO
    
    <a href='https://brc.riken.jp/mus/pcr01494'>Genotyping protocol -PCR-</a>
    
    Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol><A HREF="https://www.fbs.osaka-u.ac.jp/labs/nakano/index.html" target="_blank">Lab HP (Japanese)</A>
    Toshinobu NAKAMURA
    
    
    条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>使用目的を明らかにすること。
    Osaka Univ.
    
    
    大阪大学大学院医学研究科/生命機能研究科・中村肇伸先生、木村 透先生、仲野 徹先生(2003)。  D3 ES細胞を用いて作出。C57BL/6セミコンジェニック。
    
    
    
    B6;129S2-Dppa3<tm1(rtTA)Nkn>/NknRbrc
    B6;129S2-Dppa3<tm1(rtTA)Nkn>/NknRbrc
    
    
    
    The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. The RECIPIENT must inform the DEPOSITOR the research project using the BIOLOGICAL RESOURCE.
    
    
    
    
    Heterozygote x Wild-type [C57BL/6NCrSlc]
    Heterozygote x Wild-type [C57BL/6NCrSlc]
    true